SLN
$5.80
Silence Therapeutics Plc ADR
$.10
1.75%
SLN
Earnings Whisper ®
N/A
2nd Quarter June 2023
Consensus:  ($0.59)
Revenue:  $4.08 Mil
Tuesday
Aug 15
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when SLN reports earnings?
Beat
Meet
Miss

Where is SLN's stock price going from here?
Up
Flat
Down
Stock chart of SLN
Analysts
Summary of analysts' recommendations for SLN
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.